ライフサイエンスコーパス: nuclear factor

1 tor components Elp1, Elp2 and Elp3 and other nuclear factors.

2 Hepatocyte nuclear factor 1 homeobox alpha (HNF1alpha) is a transcr

3 ich expressed Napsin A and HNF1B (hepatocyte nuclear factor 1 homeobox B), markers of clear-cell aden

4 t-line treatment in patients with hepatocyte nuclear factor 1alpha (HNF1A) diabetes, but SUs have lim

5 In patients with multiple HCAs, hepatocyte nuclear factor 1alpha-inactivated HCAs showed a higher r

6 ly to show progressive disease, with hepatic nuclear factor 1alpha-inactivated hepatocellular adenoma

7 gous variant in the gene encoding hepatocyte nuclear factor-1alpha (HNF1A).

8 Hepatocyte nuclear factor-1beta (HNF-1beta) is a tissue-specific tr

9 Hepatocyte nuclear factor-1beta (HNF-1beta) is a tissue-specific tr

10 has a stronger homology with the hepatocyte nuclear factor 3 (HNF3)-binding site than +1164G.

11 Hepatocyte nuclear factor 4 (HNF4) family are transcription factors

12 Hepatocyte nuclear factor 4 (HNF4) transcription factor motifs are

13 the tumor-suppressive isoform of hepatocyte nuclear factor 4 alpha ("P1-HNF4alpha") in the liver in

14 Hepatocyte nuclear factor 4 alpha (HNF4A), a liver-enriched TF, act

15 egulation and activation of human hepatocyte nuclear factor 4 alpha (HNF4alpha) in a p53-dependent ma

16 ive androstane receptor (CAR) and hepatocyte nuclear factor 4 alpha (HNF4alpha) to induce CYP2B6 by p

17 ive androstane receptor (CAR) and hepatocyte nuclear factor 4 alpha (HNF4alpha).

18 g six previously unknown loci (in hepatocyte nuclear factor 4 alpha [HNF4A], fucosyltransferase 2, se

19 tment caused transient decline in hepatocyte nuclear factor 4 alpha expression concomitant to prolife

20 sive element-binding protein, and hepatocyte nuclear factor 4 alpha, were also found to be modulated

21 , both of which were dependent on hepatocyte nuclear factor 4 alpha.

22 hepatocytes were characterized by hepatocyte nuclear factor 4-alpha (HNF-4alpha) and albumin (ALB) ex

23 Here we report that hepatocyte nuclear factor 4alpha (HNF4alpha) dictates the sensitivi

24 Hepatocyte nuclear factor 4alpha (HNF4alpha) is a master regulator

25 entified that aging alters Sirtuin-1-hepatic nuclear factor 4alpha circuit in hepatocytes to downregu

26 signaling promoted nuclear translocation of nuclear factor-activated T-cells 1 (NFATc1), which was i

27 ted decoy receptor for receptor activator of nuclear factor B ligand (RANKL), plays an essential role

28 ted; however, the result suggests that these nuclear factors bind to their cognate loci, as substanti

29 Conclusion Hepatocellular carcinoma with nuclear factor E2-related factor 2 (NRF2) alterations sh

30 A subset of HCCs harbor nuclear factor E2-related factor 2 (NRF2), a major regul

31 anism that involves the transcription-factor nuclear-factor E2-related factor-2 (NRF2).

32 s and model mice of the transcription factor nuclear-factor-E2-related factor-2 (Nrf2), a major regul

33 ategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2) c

34 elch-like ECH-associating protein 1 (Keap1), nuclear factor erythroid 2 related factor 2 (Nrf2) and g

35 nscription factor Y subunit alpha (NFYa) and nuclear factor erythroid 2-like 1 (NFE2L1) transcription

36 imary cultures of rat enteric neurons and in nuclear factor erythroid 2-related factor (Nrf2) knockou

37 By exposing nuclear factor erythroid 2-related factor (Nrf2) knockou

38 t, endothelial nitric oxide synthase (eNOS), nuclear factor erythroid 2-related factor 2 (Nrf2) and h

39 Nuclear factor erythroid 2-related factor 2 (Nrf2) disso

40 ted herpesvirus (KSHV)-induced activation of nuclear factor erythroid 2-related factor 2 (Nrf2) is es

41 Nuclear factor erythroid 2-related factor 2 (Nrf2) is ub

42 The nuclear factor erythroid 2-related factor 2 (Nrf2) signa

43 at bardoxolone methyl, a potent activator of nuclear factor erythroid 2-related factor 2 (Nrf2), is e

44 tivation of aryl hydrocarbon receptor (AhR)- nuclear factor erythroid 2-related factor 2 (Nrf2)-depen

45 the balance between oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2)-depen

46 the master regulator of antioxidant defense nuclear factor erythroid 2-related factor 2 (Nrf2).

47 Increased nuclear factor erythroid 2-related factor 2 expression w

48 d antioxidant response guided by a defective Nuclear Factor Erythroid 2-Related Factor 2 pathway conf

49 Pharmacological activation of NRF2 (nuclear factor erythroid 2-related factor 2) arises from

50 hat ANG triggers the activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway, wh

51 iphosphate, hypoxia-inducible factor-1alpha, nuclear factor erythroid 2-related factor 2) suggesting

52 to F-actin reorganization and activation of nuclear factor erythroid 2-related factor 2-mediated oxi

53 Nuclear factor erythroid derived-2-related factor 2 (Nrf

54 The transcription factor nuclear factor erythroid-2-related factor 2 (Nrf2) plays

55 c disorder, we found that the cytoprotective nuclear factor erythroid-related factor 2 (Nrf2)/kelch-l

56 The nuclear factor (erythroid 2)-like (NRF) transcription fa

57 The nuclear factor (erythroid 2)-like 2 (NRF2 or NFE2L2) tra

58 sed proteasome maturation protein (POMP) and nuclear factor (erythroid-derived 2)-like 2 (NRF2) expre

59 Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a

60 The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is th

61 The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) trans

62 rmones/their receptors can attenuate altered Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), neur

63 glycogen synthase kinase 3 beta (GSK-3beta)/nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/tetra

64 Driven by the transcriptional activation of nuclear factor (erythroid-derived 2)-like 2, the master

65 that this effect is due to binding of Nrf2 (nuclear factor [erythroid-derived 2]-like 2) to 2 AREs (

66 Nuclear factor, erythroid 2 like 2 (Nrf2)-regulated gene

67 ned with a cell-protective expression of the nuclear factor, erythroid 2.

68 o the activation of the transcription factor nuclear factor, erythroid-derived 2, like 2 (Nfe2l2 or N

69 via inhibition of transcription factor Nrf2 (nuclear factor-erythroid 2 p45-related factor 2).

70 While transcription factor nuclear factor-erythroid 2-like 2 (NRF2) protects cells

71 oxygenase 1 (Hmox1) and transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2)).

72 there was no change in the expression of the nuclear factor-erythroid 2-related factor 2 and its down

73 Nuclear factor-erythroid factor 2-related factor 2 (Nrf2

74 so involves dynamic expression of hepatocyte nuclear factor (Hnf)4alpha, Yes-associated protein (Yap)

75 Analysis of hepatocyte nuclear factors (HNFs) showed that transcription of HNF4

76 Nuclear factor I (NFI)-type transcription factors regula

77 Disruption of nuclear factor I transcription factors, which maintain a

78 itional deletion of the transcription factor nuclear factor I-A (NFIA) in astrocytes in the adult bra

79 tive astrocytes, we investigated the role of nuclear factor I-A (NFIA), a key transcriptional regulat

80 cal role for the transcription factors (TFs) nuclear factor IB (NFIB) and IX (NFIX) in maintaining SC

81 Furthermore, CXXC-PHD recruits 94 nuclear factors involved in replication, ribosome synthe

82 and III IFN responses, such as inhibitor of nuclear factor kappa B (IkappaB) kinase alpha (IKKalpha)

83 ogesterone exhibited an inhibitory effect on nuclear factor kappa B (NF-kappaB) activation following

84 Nuclear factor kappa B (NF-kappaB) activation in the liv

85 alyses across technologies demonstrated that nuclear factor kappa B (NF-kappaB) and cholesterol biosy

86 Both the canonical nuclear factor kappa B (NF-kappaB) and mitogen activated

87 mily members such as p38 and JNK and induced nuclear factor kappa B (NF-kappaB) pathway activation.

88 The nuclear factor kappa B (NF-kappaB) signaling system, a k

89 We used a chick in vivo model to investigate nuclear factor kappa B (NF-kappaB) signaling, a critical

90 active and supports TGF-beta-induced EMT and nuclear factor kappa B (NF-kappaB) signaling, whereas th

91 immune pathways that are primarily driven by nuclear factor kappa B (NF-kappaB), interferon regulator

92 glucocorticoid insensitivity: respectively, nuclear factor kappa B (NF-kB), cAMP response element-bi

93 ced persistent inflammation by circumventing nuclear factor kappa B activation and its downstream cyt

94 mitogen-activated protein (MAP) kinases and nuclear factor kappa B and decreased myogenic differenti

95 itions, interferonopathies, and disorders of nuclear factor kappa B and/or aberrant TNF activity.

96 Serum receptor activator of nuclear factor kappa B ligand (RANKL) and its antagonist

97 one marrow cultures to receptor activator of nuclear factor kappa B ligand (RANKL), macrophage colony

98 s) induced the expression of EMT traits, the nuclear factor kappa B pathway, autophagy, and the loss

99 owing C. parvum infection could activate the nuclear factor kappa B signaling pathway and trigger inf

100 l infections, including interferon (IFN) and nuclear factor kappa B signaling.

101 crosis factor alpha]), as well as NF-kappaB (nuclear factor kappa B) and inflammasome activation.

102 es were associated with increased NF-kappaB (nuclear factor kappa B) binding activity and expression

103 tivated protein kinases as well as NFkappaB (nuclear factor kappa B).

104 crovascular density and higher expression of nuclear factor kappa B, interleukin-6, interleukin-8, tr

105 eraction with cyclooxygenase-2 (COX-2), p65- nuclear factor kappa B, lipoxygenase-1 (LOX-1) and toll-

106 insulin receptor, which in turn activates a nuclear factor kappa B-dependent metabolic pathway, lead

107 eceptor-4 (TLR4), high-mobility group box 1, nuclear factor kappa beta, myeloid differentiation prima

108 phorylation and nuclear translocation of the nuclear factor kappa light chain enhancer of activated B

109 ee text] ([Formula: see text]) signaling via nuclear factor kappa-B ([Formula: see text]) hallmarks (

110 ron regulatory factor 3 (IRF-3)-mediated and nuclear factor kappa-B (NF-kappaB) inhibitor (IkappaBalp

111 transcripts and an increase in inhibitors of nuclear factor kappa-B (NF-kappaB) signaling, possibly i

112 dly induces co-occupancy of KDM7A and UTX at nuclear factor kappa-B (NF-kappaB)-associated elements i

113 ion of RelA (p65), thus repressing oncogenic nuclear factor kappa-B (NF-kB) signaling and inducing ap

114 f clinical parameters, receptor activator of nuclear factor kappa-B (RANKL) and osteoprotegerin (OPG)

115 igated if ILCs express receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine crucia

116 ctivator-related gene, receptor activator of nuclear factor kappa-B ligand, and osteoblast differenti

117 Serum receptor activator of nuclear factor kappa-Beta ligand (RANKL) and sclerostin

118 Using receptor activator of nuclear factor kappa-Beta ligand (RANKL) induced osteocl

119 nducible expression of receptor-activator of nuclear factor kappa-Beta ligand (Rankl) leads to ectopi

120 d a decrease in RANKL (receptor activator of nuclear factor kappa-Beta ligand) mRNA expression in the

121 ference to expression of Bcl-2, Bax, Bcl-xL, nuclear factor kappa-light chain enhancer of activated B

122 antagonist; or parthenolide, a caspase-1 and nuclear factor kappa-light-chain-enhancer of activated B

123 ld increases in SOD2 acetylation, NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B

124 ker upregulates phospho-signaling within the nuclear factor kappa-light-chain-enhancer of activated B

125 c-Jun N-terminal kinase pathways and reduced nuclear factor kappa-light-chain-enhancer of activated B

126 Here, we identify nuclear factor kappa-light-chain-enhancer of activated B

127 w a series of maturation programs, including nuclear factor kappa-light-chain-enhancer of activated B

128 egulated transcription coactivator-1, Jacob, nuclear factor kappa-light-chain-enhancer of activated B

129 is determined by the degree of activation of nuclear factor kappa-light-chain-enhancer of activated B

130 Internalized MAC stabilize NIK (NF-kappaB [nuclear factor kappa-light-chain-enhancer of activated B

131 Nuclear factor kappa-light-chain-enhancer of activated B

132 nsducer and activator of transcription 3 and nuclear factor kappa-light-chain-enhancer of activated B

133 actor receptor 1 (TNFR1) activation controls nuclear factor kappa-light-chain-enhancer of activated B

134 ntrols whether the cell undergoes NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B

135 e (MAPK), Jun NH2-terminal kinase (JNK), and nuclear factor kappa-light-chain-enhancer of activated B

136 H. pylori-induced nuclear factor kappa-light-chain-enhancer of activated B

137 , JAK3 or Wnt3a inhibition robustly enhances nuclear factor kappa-light-chain-enhancer of activated B

138 med for IL6 and p65 translocation, a subunit nuclear factor kappa-light-chain-enhancer of activated B

139 myddosome, results in maximal activation of nuclear factor kappa-light-chain-enhancer of B cells (NF

140 At concentrations that activated nuclear factor-kappa B (NF-kappaB) in LUHMES cells, EMA

141 D137 ligand and CD40 initiates activation of nuclear factor-kappa B (NF-kappaB) signaling in tumor ce

142 AT3, c-jun n-terminal kinases (JNK), EKR1/2, nuclear factor-kappa B (NF-kappaB)) in the gastrocnemius

143 We exploited the Nuclear Factor-kappa B (NF-kB) signal transduction pathw

144 on and location of the receptor activator of nuclear factor-kappa B (RANKL) and of osteoprotegerin (O

145 ecrease in hepatic fibrosis (p < 0.001), and nuclear factor-kappa B activity (p < 0.05) as compared w

146 osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B ligand (RANKL), increased osterix

147 ing factor (M-CSF) and receptor activator of nuclear factor-kappa B ligand (RANKL).

148 The effects of CLIC4 on NF-kappaB (nuclear factor-kappa B), HIF (hypoxia-inducible factor),

149 noncanonical members of the inhibitor of the nuclear factor kappaB (IkappaB) kinase family.

150 that only BBzeta CARs activated noncanonical nuclear factor kappaB (ncNF-kappaB) signaling in T cells

151 ion of NOTCH2 (pL2.Lgr5.N2fl/fl), or loss of nuclear factor kappaB (NF-kappaB) (pL2.Lgr5.p65fl/fl), i

152 Similarly to Parkin, PACRG promoted nuclear factor kappaB (NF-kappaB) activation in response

153 component that promotes glycolysis, but not nuclear factor kappaB (NF-kappaB) activation.

154 hich operates in parallel to Toll to control nuclear factor kappaB (NF-kappaB) activity and independe

155 sing high-throughput screens with cell-based nuclear factor kappaB (NF-kappaB) and interferon stimula

156 ptor proteins, transcription factors such as nuclear factor kappaB (NF-kappaB) and TCF3, as well as w

157 istribution of Dorsal (Dl), a homolog of the nuclear factor kappaB (NF-kappaB) family of transcriptio

158 is question for transcription factors of the nuclear factor kappaB (NF-kappaB) family, we profiled th

159 ypoferremia to infection requires Drosophila nuclear factor kappaB (NF-kappaB) immune pathways, Toll

160 rocytes in MS and EAE.SIGNIFICANCE STATEMENT Nuclear factor kappaB (NF-kappaB) is activated in oligod

161 Here, we demonstrate that RB interacts with nuclear factor kappaB (NF-kappaB) protein p65 and that t

162 across millions of cells for involvement in nuclear factor kappaB (NF-kappaB) signaling by imaging t

163 Because inflammation mediated by nuclear factor kappaB (NF-kappaB) signaling is implicate

164 determine the relationship between SETD1 and nuclear factor kappaB (NF-kappaB) through its activation

165 ression correlated with potent activation of nuclear factor kappaB (NF-kappaB), a well-known transcri

166 tion of EGLN3, a known negative regulator of nuclear factor kappaB (NF-kappaB), as a direct target of

167 (cHL), including constitutive activation of nuclear factor kappaB (NF-kappaB), JAK/STAT signaling, a

168 tion by activating a strong and specific p65-nuclear factor kappaB (NF-kappaB)-dependent gene program

169 rdinated activation of NOD2 and ATG16L1 by a nuclear factor kappaB (NF-kappaB)-independent pathway.

170 (ATF4) but are accompanied by activation of nuclear factor kappaB (NF-kappaB).

171 e gene encoding CARD14, a major regulator of nuclear factor kappaB (NF-kappaB).

172 e for the innate immune transcription factor nuclear factor kappaB (NF-kappaB)/Relish in governing li

173 otic pathway- tumor necrosis factor alpha -> nuclear factor kappaB -> caspase-3, increased expression

174 lelic null mutations), B-cell expansion with nuclear factor kappaB and T-cell anergy (heterozygous, g

175 thelial LOX expression through activation of nuclear factor kappaB and TGF-beta-mediated signaling.

176 n and function through TLR4 and inhibitor of nuclear factor kappaB kinase activation.

177 bitor of MMP (TIMP)-1, receptor activator of nuclear factor kappaB ligand (RANKL), and osteoprotegeri

178 teolytic factor termed receptor activator of nuclear factor kappaB ligand (RANKL), which is responsib

179 ast function, possibly through the canonical nuclear factor kappaB pathway and the Akt-glycogen synth

180 Sustained intra-acinar activation of nuclear factor kappaB pathway seems to be key pathogenic

181 ransducer and activator of transcription and nuclear factor kappaB pathways, and provide additional e

182 upregulate feedback inhibitors of the MyD88-nuclear factor kappaB signaling pathway.

183 ILK-enriched exosomes activated NF-kappaB (nuclear factor kappaB) pathway and NF-kappaB-dependent g

184 NF-kappaB (nuclear factor kappaB) signaling is considered critical

185 The peptide also affected the TLR4-(nuclear factor kappaB) signaling pathway, modulating the

186 response, TP53 (tumor protein 53), NFkappaB (nuclear factor kappaB), and TGFbeta (transforming growth

187 on of protein kinase B, also known as (AKT), nuclear factor kappaB, and beta-catenin.

188 ation of tumor suppressor proteins, inhibits nuclear factor kappaB, and reduces oncoprotein messenger

189 ptor engagement with downstream signaling to nuclear factor kappaB, c-Jun N-terminal kinase, and mech

190 mitogen-activated protein kinase (MAPK)- and nuclear factor kappaB-dependent induction of reactive ox

191 othelial cells expressing the LTbetaR target nuclear factor kappaB-inducing kinase (NIK) decreased in

192 volves MEK1/2/pERK1/2, MEK5/pERK5, PI3K, and nuclear factor kappaB.

193 regulatory factor 3 (IRF3) and inhibitor of nuclear factor-kappaB (IkappaB) kinase (IKK)/nuclear fac

194 T1D caused aberrant nuclear factor-kappaB (NF-kappaB) activation in SSCs and

195 tein) Ser239 residue which, in turn, reduced nuclear factor-kappaB (NF-kappaB) activity and Il1b and

196 GBM tumors show nuclear factor-kappaB (NF-kappaB) activity that has been

197 Activation of transcription factors, nuclear factor-kappaB (NF-kappaB) and c-Fos-p-38, was ob

198 idence for involvement of AQP3 expression in nuclear factor-kappaB (NF-kappaB) cell signaling, hepati

199 n about the role of the transcription factor nuclear factor-kappaB (NF-kappaB) in this process.

200 duced nuclear content of S536-phosphorylated nuclear factor-kappaB (NF-kappaB) subunit p65, lower nit

201 transmethylation reactions, translocation of nuclear factor-kappaB (NF-kappaB) to the nucleus, signal

202 These gene products are regulated by the nuclear factor-kappaB (NF-kappaB) transcriptional comple

203 growth arrest and the transcription factor, nuclear factor-kappaB (NF-kappaB), contribute to cancer

204 ; phosphatase and tensin homolog (PTEN); and nuclear factor-kappaB (NF-kappaB).

205 eptor 4 (TLR4), which links to activation of nuclear factor-kappaB (NF-kappaB).

206 matory effects by interacting with activated nuclear factor-kappaB (NF-kappaB)/p65.

207 nuclear factor-kappaB (IkappaB) kinase (IKK)/nuclear factor-kappaB (NFkappaB) signaling cascades.

208 that inhibition of the receptor activator of nuclear factor-kappaB (RANK) signaling pathway may enhan

209 associated with decreasing inflammation and nuclear factor-kappaB activation.

210 mpared with control mice and associated with nuclear factor-kappaB activation.

211 onserved protein, originally identified as a nuclear factor-kappaB activator through a large-scale sc

212 ells, allowing for coordinated activation of nuclear factor-kappaB and downregulation of interferon-a

213 testinal barrier dysfunction by blocking the nuclear factor-kappaB and myosin light chain kinase-medi

214 tion of the pleiotropic transcription factor nuclear factor-kappaB and therefore the induction of ath

215 Interestingly, the activation of nuclear factor-kappaB by CCN1/alpha6beta1 signaling prom

216 elated with serum zonulin and phosphorylated nuclear factor-kappaB expression.

217 phoinositide 3-kinase-gamma, and p50 and p65 nuclear factor-kappaB in such inhibitory action of IL-33

218 Receptor activator of nuclear factor-kappaB ligand (RANKL) constitutes the mas

219 oclastogenic cytokine receptor activator for nuclear factor-kappaB ligand (RANKL).

220 ere used to assess the variant impact on the nuclear factor-kappaB pathway and lymphocyte function.

221 Genetic faults in several components of the nuclear factor-kappaB pathway cause immunodeficiency.

222 This was associated with blockade of nuclear factor-kappaB pathway signaling, resulting in ab

223 esponse genes, followed by activation of the nuclear factor-kappaB pathway.

224 methyltransferase SETD6 in the activation of nuclear factor-kappaB RELA (also known as transcription

225 e that SETD6 is necessary for memory-related nuclear factor-kappaB RELA methylation at lysine 310 and

226 rove exaggerated transcription of late-phase nuclear factor-kappaB response genes in vitro and in pre

227 s of these peroxides are interconnected with nuclear factor-kappaB signaling and NO production.

228 in the pathogenesis of ACM, we characterized nuclear factor-kappaB signaling in ACM models in vitro a

229 sed activation of the hexosamine pathway and nuclear factor-kappaB signaling to elevate TSP2 expressi

230 Nuclear factor-kappaB signaling was also activated in ca

231 Activation of nuclear factor-kappaB signaling, indicated by increased

232 Bay 11-7082, a small-molecule inhibitor of nuclear factor-kappaB signaling, prevented the developme

233 atory pathways such as type I interferon and nuclear factor-kappaB signaling.

234 effect related to changes in Keap1/Nrf2 and nuclear factor-kappaB signalling.

235 de inhibited oxidized LDL-induced NF-kappaB (nuclear factor-kappaB) activation and inflammatory cytok

236 eceptor that negatively regulates NF-kappaB (nuclear factor-kappaB) signaling.

237 back regulation between CCN1/alpha6beta1 and nuclear factor-kappaB, and prevented flow-induced athero

238 d by preventing DON-induced translocation of nuclear factor-kappaB, as well as activation of mitogen-

239 Rather than stimulating nuclear factor-kappaB, radiation-activated IRAK1 prevent

240 ress-response transcription factors NRF2 and nuclear factor-kappaB, the role of trace elements such a

241 ts receptor integrin alpha6beta1 to activate nuclear factor-kappaB, thereby instigating a vicious cir

242 d Delta(9)-THC synergistically activated the nuclear factor-kappaB-cyclooxygenase-2 pathway in astroc

243 ed innate immune response with signatures of nuclear factor-kappaB-dependent, type I and II interfero

244 osphorylation of IFN regulatory factor 3 and nuclear factor-kappaB.

245 or gain-of-function heterozygous variants in nuclear factor-kappaB2 have been reported to be associat

246 centrations of soluble receptor activator of nuclear factor-kappabeta ligand (sRANKL), and osteoprote

247 luble and nuclear forms, and subsequently to nuclear factor-kB (NF-kB) activation and secretion of va

248 inephrine and serotonin levels and decreased nuclear factor-kB, tumor necrosis factor-alpha and inter

249 ia activation (IBA-1), phospho-P38 MAPK, and nuclear factor NF-kappaB inflammatory pathways were also

250 , the regulatory subunit of the inhibitor of nuclear factor (NF)- kappaB kinase complex.

251 oliferation, and assays for Wnt signaling or nuclear factor (NF)-kappa-B activity.

252 lator of inflammation through termination of nuclear factor (NF)-kappaB activation as part of a negat

253 ric tissue was used for the determination of nuclear factor (NF)-kappaB expression by immunohistochem

254 Additionally, nuclear factor (NF)-kappaB inhibition was performed with

255 RvD1 also reduced activation of the nuclear factor (NF)-kappaB pathway and reduced the expre

256 The nuclear factor (NF)-kappaB pathway plays a central role

257 The transcription factor nuclear factor (NF)-kappaB promotes inflammatory and str

258 (TNF), the master transcriptional regulator nuclear factor (NF)-kappaB utilizes the PPM1G/PP2Cgamma

259 vated interferon (IFN)-gamma production in a nuclear factor (NF)-kappaB-T-bet-dependent manner.

260 bits the altered Ca(2+) signaling, increased nuclear factor (NF)-kappaB/cyclin D1 activation and cell

261 ndance of transcription factor EB (TFEB) and nuclear factor of activated T cells (NFAT) and potentiat

262 the disease process is the activation of the nuclear factor of activated T cells (NFAT) c3 in lung ma

263 The transcription factor nuclear factor of activated T cells (NFAT) has a key rol

264 ly demonstrated that hyperglycemia activates nuclear factor of activated T cells (NFAT) in conduit an

265 s revealed that dysregulation of calcineurin-nuclear factor of activated T cells (NFAT) signaling and

266 t al investigate the role of calcium-induced nuclear factor of activated T cells (NFAT) signaling in

267 um conductance results in the stimulation of nuclear factor of activated T cells (NFAT) that triggers

268 ar translocation of the transcription factor nuclear factor of activated T cells (NFAT) with a simila

269 RP)-C1-mediated calcium entry and downstream nuclear factor of activated T cells (NFAT)-transcription

270 activating transcription factor 4 (ATF4) and nuclear factor of activated T cells (NFAT).

271 of the Ca(2+)-dependent transcription factor nuclear factor of activated T cells (NFAT).

272 has been suggested to have a unique role in nuclear factor of activated T cells 1 (NFAT1) activation

273 Moreover, MLK3 also phosphorylates nuclear factor of activated T cells 1 (NFATc1) and regul

274 been revealed with the participation of the nuclear factor of activated T cells 1 (Nfatc1), Runx3, a

275 rt of the osteogenic transcription regulator nuclear factor of activated T cells 1 (NFATC1).

276 Nuclear Factor of Activated T cells 5 (NFAT5) is a trans

277 and stimulation of the transcription factor nuclear factor of activated T cells 5 (NFAT5).

278 by the initiating transcription factor NFAT (nuclear factor of activated T cells)(10-12).

279 in the BCR-calcineurin pathway, including a nuclear factor of activated T cells, cytoplasmic 1 (NFAT

280 lc7a5 deficiency increased the expression of nuclear factor of activated T cells, cytoplasmic 1 (Nfat

281 act of USSN is in initiation of the primary, nuclear factor of activated T cells-pathway signaling fr

282 with increased nuclear translocation of the nuclear factor of activated T cells.

283 by upregulating IPLs in manner dependent on nuclear factor of activated T cells.

284 tal muscle differentiation, Cn activates the nuclear factor of activated T-cell (NFAT) transcription

285 -responsive enhancer binding protein (TonEBP/nuclear factor of activated T-cell5 [NFAT5])-mediated os

286 lin-dependent phosphatase calcineurin toward nuclear factor of activated T-cells (NF-AT) in T-lymphoc

287 n of activity-dependent transcription by the nuclear factor of activated T-cells (NFAT) depends upon

288 dent P2X4 and P2X7 activation, activation of nuclear factor of activated T-cells (NFAT) transcription

289 ation, migration and nuclear localization of nuclear factor of activated T-cells (NFATc1 and c3) were

290 ll-specific transmembrane protein (DCSTAMP), nuclear factor of activated T-cells (NFATc1), and osteoc

291 t number (P < 0.05) as well as the levels of nuclear factor of activated T-cells cytoplasmic 1, NF-ka

292 e assessed by functional in vitro testing of nuclear factor of kappa light polypeptide gene enhancer

293 Expression of nuclear factor of kappa light polypeptide gene enhancer

294 e the nucleolus and the transcription factor nuclear factor of kappa-light-chain-enhancer of activate

295 ne TF that contributes to these processes is Nuclear Factor One X (NFIX).

296 rgeted loss-of-function screen of around 500 nuclear factors to identify gene regulatory programs tha

297 se that CXXC-PHD promotes permissiveness for nuclear factors to interact, but involvement of the XRCC

298 Here we identify the nuclear factor TOX as a crucial regulator of the differe

299 Here, a root-specific nuclear factor Y (NF-Y) transcription factor PdNF-YB21 w

300 Arabidopsis transcription factors identifies nuclear factor Y subunit C10 (NF-YC10) as a GAPC-binding